You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms: Spotlight on New Data From New Orleans 2022

  • Authors: Eunice S. Wang, MD; Amer Zeidan, MBBS, MHS; John Mascarenhas, MD
  • CME / ABIM MOC Released: 1/18/2023
  • Valid for credit through: 1/18/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists and other healthcare professionals (HCPs) involved in the care of patients with myeloid malignancies.

The goal of this activity is to improve learners’ knowledge of new clinical data presented at the 2022 American Society of Hematology (ASH) annual meeting related to the management of myeloid malignancies (acute myeloid leukemia [AML], myelodysplastic syndrome [MDS], and myeloproliferative neoplasms [MPNs]), and to improve physician confidence in integrating these data into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical trial data on myeloid malignancies
  • Demonstrate greater confidence in their ability to
    • Assess the implications of recent clinical trial data in the field of myeloid malignancies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Eunice S. Wang, MD

    Professor of Oncology
    Chief, Leukemia Service
    Director
    Roswell Park Comprehensive Cancer Institute
    Buffalo, New York

    Disclosures

    Eunice S. Wang, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Amgen, Inc.; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Mana Therapeutics; Novartis; NuProbe; PharmaEssentia; Pfizer, Inc.; Stemline; Takeda
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; Dava Oncology, Pfizer, Inc.; Stemline
    Research funding from: Amgen, Inc.; Aptevo Therapeutics; AROG Pharmaceuticals, INC.; Cellectis; Gilead Sciences, Inc.; ImmunoGen, Inc.; Incyte Corporation; Loxo Oncology; Pfizer, Inc.; Stemline

  • Amer Zeidan, MBBS, MHS

    Associate Professor of Internal Medicine (Hematology)
    Yale Cancer Center and Smilow Cancer Hospital
    Yale University School of Medicine
    New Haven, Connecticut

    Disclosures

    Amer Zeidan, MBBS, MHS, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Acceleron Pharma, Inc.; Agios Pharmaceuticals; Amgen, Inc.; Aprea Therapeutics; Astellas Pharma, Inc.; BeyondSpring; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardiff Oncology; Cardinal Health; Celgene Corporation/Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Epizyme Inc.; Geron; Gilead Sciences, Inc.; Incyte Corporation; Ionis Pharmaceuticals; Janssen; Jazz Pharmaceuticals, Inc.; Kura; Novartis; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Seagen Inc.; Syndax Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; Takeda; Trovagene; Tyme
    Research funding from: AbbVie Inc.; ADC Therapeutics; Amgen, Inc.; Aprea Therapeutics; Astex Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardiff Oncology; Celgene/Bristol Myers Squibb Company; Incyte Corporation; MedImmune Inc./AstraZeneca Pharmaceuticals LP; Novartis; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Takeda; Trovagene
    Other: TRAVEL SUPPORT: Cardiff Oncology; Novartis; Pfizer, Inc. CLINICAL TRIAL COMMITTEES: AbbVie Inc.; Celgene Corporation/Bristol Myers Squibb Company; Geron; Gilead Sciences, Inc.; Kura; Novartis. HONORARIA: AbbVie Inc.; Acceleron Pharma, Inc.; Agios Pharmaceuticals; Amgen, Inc.; Aprea Therapeutics; Astellas Pharma, Inc.; BeyondSpring; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardiff Oncology; Cardinal Health; Celgene Corporation/Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Epizyme Inc.; Geron; Gilead Sciences, Inc.; Incyte Corporation; Ionis Pharmaceuticals; Janssen; Jazz Pharmaceuticals, Inc.; Kura; Novartis; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Seagen Inc.; Taiho Pharmaceutical Co., Ltd.; Syndax Pharmaceuticals, Inc.; Takeda; Trovagene; Tyme

  • John Mascarenhas, MD

    Professor of Medicine
    Tisch Cancer Institute
    Icahn School of Medicine at  Mount Sinai
    New York, New York

    Disclosures

    John Mascarenhas, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Bristol Myers Squibb Company; Celgene Corporation; Constellation; CTI BioPharma Corp.; Galecto; Geron; Imago Pharmaceuticals; Incyte Corporation; Kartos; Karyopharm; Novartis; PharmaEssentia; Roche
    Research funding from: AbbVie Inc.; Bristol Myers Squibb Company; Celgene Corporation; CTI BioPharma Corp.; Geron; Incyte Corporation; Kartos; Merck; Novartis; PharmaEssentia, Roche 

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms: Spotlight on New Data From New Orleans 2022

Authors: Eunice S. Wang, MD; Amer Zeidan, MBBS, MHS; John Mascarenhas, MDFaculty and Disclosures

CME / ABIM MOC Released: 1/18/2023

Valid for credit through: 1/18/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Acute Myeloid Leukemia

Dr Wang reviews the biggest AML news from the ASH 2022 annual meeting.
Eunice S. Wang, MD

Myelodysplastic Syndrome

Dr Zeidan provides an overview of ASH 2022 clinical trial updates in MDS.
Amer Zeidan, MBBS, MHS

Myeloproliferative Neoplasms

Dr Mascarenhas highlights studies in MPNs presented at the December 2022 ASH meeting.
John Mascarenhas, MD
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print